Suraksha Diagnostic Limited (SURAKSHA)

Loading page…

Suraksha Diagnostic Limited (SURAKSHA) · mywealthgrid

About

Diagnostic services provider in healthcare sector. Market cap ₹1,588 Cr. Quarterly revenue ₹70–81 Cr. Positioned in India's mid-cap diagnostics market.

Face value: ₹2

Market cap

₹1,824 Cr

P/E

51.0×

P/B

7.5×

Dividend yield

0.1%

ROE

14.1%

ROCE

16.8%

Debt / equity

0.01

OPM

30.7%

EPS (TTM)

₹6.9

Book value

₹47.0

52-week high

—

52-week low

Key insights

Company research notes and source-linked reviews

Key risks

OPM compressed 33.92% → 30.32% (Jun '25 to Mar '26). Cost drivers unclear; verify source of margin squeeze.

Net profit down 32% (₹9.85 Cr → ₹6.71 Cr, Jun '25 to Mar '26) despite revenue growth. Investigate efficiency or pricing erosion.

PE 49.35 expensive for current earnings trend. Market prices recovery not visible in recent quarters.

Competitive diagnostics market. Verify Suraksha's differentiation, pricing power, customer retention vs peers.

Generated analysis · source review pending

Growth drivers

Revenue growing ₹70.28 Cr (Jun '25) → ₹78.56 Cr (Mar '26, ~12% growth). Verify volume vs pricing contribution.

Low debt (D/E 0.01) frees capex for geographic or service expansion. Verify capex roadmap and branch pipeline.

India's healthcare diagnostics sector expanding (preventive care, insurance adoption). Verify Suraksha's market-share gains vs sector growth rate.

Strong cash generation (₹6.71–9.85 Cr quarterly net profit) supports organic capex. Verify allocation to expansion vs shareholder returns.

Generated analysis · source review pending

447 historical price candles were omitted because the exchange source has not been verified.

₹350.2-1.4%1Y

Quick read

rule-based

Pros

+Healthy operating margin of 30.7%
+Almost debt-free (debt/equity 0)

Cons

−Low dividend payout of 7.3% of profit

Research score

Structured signal from quality, growth, valuation and momentum.

61/100

Business quality: 57
Growth: 93
Valuation: 32

Revenue & net profit

₹ crore, by fiscal year

RevenuePAT

Margins

% of revenue, by fiscal year

OPMPAT margin

Peers

Comparable companies from the narrowest available industry classification.

Screen this industry

Loading peers…

Financials

Reported profit and loss, balance sheet, cash flow and growth history.

Annual Quarterly

Consolidated Standalone

Consolidated figures · ₹ crore

₹ Cr	Mar 2024	Mar 2025	Mar 2026
	219	252	310
COGS	27	30	36
Gross profit	191	223	274
	121	141	179
	70	81	95
OPM %	32%	32.2%	30.7%
Depreciation	33	35	41
Interest	9	8	13
	3	4	3
Profit before tax	31	41	45
Tax	8	10	13
Tax %	26.5%	25.2%	29.5%
	23	31	31
PAT margin %	10.6%	12.3%	10.1%
EPS (₹)	—	6	6.2
EPS adjusted (₹)	5.4	6.1	6.2
	—	0%	8.1%
Annual report	—	Annual report for Mar 2025	—

₹ Cr	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity capital	9	9	10	10
Reserves	—	171	201	234
	—	90	6	2
	—	30	116	202
Total equity & liabilities	—	300	334	448
	195	212	223	315
CWIP	—	1	10	35
Investments	—	0	1	0
	—	87	99	98
Total assets	—	300	334	448

₹ Cr	Mar 2024	Mar 2025	Mar 2026
	60	63	82
	-35	-40	-52
	-25	-24	-29
Net cash flow	0	-0	1
Free cash flow	15	21	14
CFO / Operating profit %	86.3%	78%	85.8%

Compounded sales growth

7 years: —
5 years: —
3 years: —
1 year: 23%

Compounded profit growth

7 years: —
5 years: —
3 years: —
1 year: 1%

Return on equity

7 years: —
5 years: —
3 years: 14%
Last year: 13%

Loading financials…

Ratios

Annual operating, return, leverage and working-capital ratios.

Consolidated Standalone

Consolidated figures

Ratio	Mar 2024	Mar 2025	Mar 2026
Margins
Gross margin %	87.5%	88.3%	88.2%
EBITDA margin %	32%	32.2%	30.7%
EBIT margin %	17.1%	18.2%	17.4%
PAT margin %	10.6%	12.3%	10.1%
Working capital
Receivable days	15	20	27
Inventory days	89	100	81
Payable days	193	169	209
NWC days	-88	-49	-101
Leverage
Current ratio	1.84	1.1	1.05
Debt to EBITDA	1.29	0.07	0.02
Debt to equity	0.5	0.03	0.01
Interest coverage	4.7	5.9	4.5
Asset turnover	0.73	0.76	0.69
Return ratios
Return on assets %	7.7%	9.3%	7%
Return on capital employed %	15.7%	18.1%	16.8%
Return on equity %	12.9%	14.7%	12.8%

Derived from reported annual statements. ROCE uses EBIT over capital employed (total assets less current liabilities). Day counts average the opening and closing balance; receivables turn on revenue, inventory and payables on cost of goods sold.

Loading ratios…

Shareholding

Quarterly ownership, named holders, insider transactions and disclosed deals.

Quarterly Annual

Every quarter filed · % of equity

Holder (%)	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
	48.78%	48.78%	48.78%	48.88%	48.98%	49%	49.1%	49.1%
	15.64%	15.39%	14.46%	13.95%	13.72%	13.46%	13.46%	13.47%
	16.68%	20.44%	22.05%	22.37%	21.98%	22.57%	23.14%	23.23%
Government	0%	0%	0%	0%	0%	0%	0%	0%
	18.9%	15.39%	14.71%	14.8%	15.32%	14.97%	14.3%	14.2%
No. of shareholders	—	—	—	—	75,304	70,963	67,107	64,866

Loading shareholding…

F&O

Current futures and options contracts with compact option-chain pages.

Not in the F&O segment

Only about 210 stocks have listed futures and options. Contracts appear here for those, refreshed after each close.

Loading f&o…

Fund holders

Mutual-fund schemes that disclosed a holding in the company.

Portfolio month

Schemes holding

across 3 fund houses

Held by these funds

14.46%

of the company's equity

All mutual funds

20.05%

shareholding pattern, Jun 2026

Portfolios as of

August 2026

compared with July 2026

3 schemes · 3 fund houses

		Shares
PHARMA FUND	Nippon India Mutual Fund	38.96 L	131.91	1.39%	7.479%	-0
Portfolio of Kotak Small Cap Fund	Kotak Mahindra Mutual Fund	36.38 L	123.16	0.63%	6.983%	+2.5 L
(Investment Manager for Motilal Oswal Mutual Fund)	Motilal Oswal Mutual Fund	543	0.02	0.04%	0.001%	+1

Loading fund holders…

Documents

Annual reports, exchange filings, offer documents, ratings and earnings-call material.

Announcements

Annual reports

Annual Report FY2025from bse Summary

Credit ratings

Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 for Credit Rating Migration9 Oct 2025

Investor Presentation and earnings call

Aug 2026Transcript AI SummaryPPTREC
May 2026Transcript AI Summary PPT REC

Documents link to external sources (exchange filings, company investor pages).

Loading documents…

Events

Upcoming dates and the company’s corporate-action history.

1

Final dividend15 Sept 2026 · ex-date₹0.5

Loading events…

Announcements

Latest exchange announcements, filings and downloadable documents.

1 month 3 months 6 months 1 year All

12 announcementsExport CSV

28 Sept 2026, 1:45 pmInsider Trading / SAST

Closure of Trading Window

Closure of Trading Window PDF

22 Sept 2026, 6:27 pmAGM/EGM

Shareholder Meeting / Postal Ballot-Outcome of AGM

AGM PDF

31 Aug 2026, 3:46 pmCompany Update

Announcement under Regulation 30 (LODR)-Newspaper Publication

Newspaper Publication PDF

27 Aug 2026, 7:48 pmCompany Update

Intimation Under Regulation 30 And 36(1)(B) Of The Securities And Exchange Board Of India (Listing Obligations & Disclosure Requirements) Regulations, 2015 (SEBI Listing Regulations)

General PDF

27 Aug 2026, 7:39 pmAGM/EGM

Notice For The 21St Annual General Meeting (AGM) Of The Company

AGM PDF

27 Aug 2026, 7:35 pmOthers

Reg. 34 (1) Annual Report.

Reg. 34 (1) Annual Report PDF

25 Aug 2026, 12:28 pmCompany Update

Announcement under Regulation 30 (LODR)-Newspaper Publication

Newspaper Publication PDF

25 Aug 2026, 11:49 amCompany Update

Announcement under Regulation 30 (LODR)-Newspaper Publication

Newspaper Publication PDF

Date	Category	Subject	Filing
28 Sept 2026, 1:45 pm	Insider Trading / SAST Closure of Trading Window	Closure of Trading Window	PDF
22 Sept 2026, 6:27 pm	AGM/EGM AGM	Shareholder Meeting / Postal Ballot-Outcome of AGM

Loading announcements…

Ratio	Mar 2024	Mar 2025	Mar 2026
Margins
Gross margin %	87.5%	88.3%	88.2%
EBITDA margin %	32%	32.2%	30.7%
EBIT margin %	17.1%	18.2%	17.4%
PAT margin %	10.6%	12.3%	10.1%
Working capital
Receivable days	15	20	27
Inventory days	89	100	81
Payable days	193	169	209
NWC days	-88	-49	-101
Leverage
Current ratio	1.84	1.1	1.05
Debt to EBITDA	1.29	0.07	0.02
Debt to equity	0.5	0.03	0.01
Interest coverage	4.7	5.9	4.5
Asset turnover	0.73	0.76	0.69
Return ratios
Return on assets %	7.7%	9.3%	7%
Return on capital employed %	15.7%	18.1%	16.8%
Return on equity %	12.9%	14.7%	12.8%

5 disclosures

Person	Deal	Shares	Value	Holding	Filed
Ritu MittalPromoters	BuyMarket Purchase	19,130	₹57.71 L	15.89% → 15.93%	29 Sept 20257(2)
Dr. Somnath ChatterjeePromoters	BuyMarket Purchase	7,800	₹24.75 L	5.08% → 5.10%	18 Aug 20257(2)
Dr. Somnath ChatterjeePromoters	BuyMarket Purchase	8,200	₹24.8 L	5.07% → 5.08%	14 Aug 20257(2)
Dr. Somnath ChatterjeePromoters	BuyMarket Purchase	8,235	₹24.78 L	5.05% → 5.07%	13 Aug 20257(2)
Dr. Somnath ChatterjeePromoters	BuyMarket Purchase	8,190	₹24.78 L	5.03% → 5.05%	13 Aug 20257(2)

Disclosed under SEBI’s insider-trading regulations, which require a filing only above ₹10 lakh in a quarter — smaller dealings are in no disclosure. Holdings are the filer’s own percentages, not recomputed.

6 deals · 6 Dec 2024 – 27 May 2025

Date	Client	Type	Venue	Side	Quantity	Price	Value
27 May 2025	INTEGRATED CORE STRATEGIES (ASIA) PTE. LTD.	Block	BSE	Sell	2,96,032	₹338.00	₹10.01 Cr
27 May 2025	BNP PARIBAS FINANCIAL MARKETS	Block	BSE	Buy	2,96,032	₹338.00	₹10.01 Cr
27 May 2025	INTEGRATED CORE STRATEGIES (ASIA) PTE. LTD.	Bulk	BSE	Sell	2,96,032	₹338.00	₹10.01 Cr
27 May 2025	BNP PARIBAS FINANCIAL MARKETS	Bulk	BSE	Buy	2,96,032	₹338.00	₹10.01 Cr
6 Dec 2024	AAKRAYA RESEARCH LLP	Bulk	NSE	Sell	3,76,606	₹435.05	₹16.38 Cr
6 Dec 2024	AAKRAYA RESEARCH LLP	Bulk	NSE	Buy	3,76,606	₹434.91	₹16.38 Cr

1–6 of 6

1 / 1

Bulk deals are a client trading over 0.5% of the equity in a session, aggregated across their trades; block deals are single negotiated trades in the exchange’s block window. Each is reported by the exchange it was crossed on, so NSE and BSE rows are separate trades rather than the same trade twice.

Company	Mkt Cap	EV	Revenue	EBITDA	OPM	PAT	NPM	ROCE	ROE	WC Days
Dr. Lal Path Labs Ltd.LALPATHLABLALPATHLAB	₹33,605 Cr	₹33,605 Cr	₹2,891 Cr	₹838 Cr	28.3%	₹542 Cr	18.5%	28.8%	21.6%	-79
Vijaya Diagnostic Centre LimitedVIJAYAVIJAYA	₹14,694 Cr	₹14,694 Cr	₹857 Cr	₹362 Cr	41.4%	₹187 Cr	21.3%	21.3%	19.7%	-117
Metropolis Healthcare LimitedMETROPOLISMETROPOLIS	₹11,151 Cr	₹11,169 Cr	₹1,710 Cr	₹422 Cr	24.4%	₹202 Cr	11.6%	17.3%	13.4%	-57
Thyrocare Technologies LimitedTHYROCARETHYROCARE	₹8,495 Cr	₹8,495 Cr	₹876 Cr	₹282 Cr	31.6%	₹176 Cr	19.6%	36.5%	28.8%	4
Nephrocare Health Services LimitedNEPHROPLUSNEPHROPLUS	₹6,509 Cr	₹6,589 Cr	₹999 Cr	₹227 Cr	22.7%	₹77 Cr	7.7%	17.1%	9.1%	-61
Suraksha Diagnostic LimitedSURAKSHASURAKSHA	₹1,824 Cr	₹1,826 Cr	₹325 Cr	₹102 Cr	30.7%	₹36 Cr	10.1%	16.8%	14.1%	-101
Krsnaa Diagnostics LimitedKRSNAAKRSNAA	₹1,798 Cr	₹2,332 Cr	₹815 Cr	₹218 Cr	27.4%	₹97 Cr	13.1%	13.1%	10.9%	65
3b Blackbio Dx Limited3BBLACKBIO3BBLACKBIO	₹1,416 Cr	₹1,417 Cr	₹96 Cr	₹50 Cr	52%	₹163 Cr	49.4%	25.3%	19.4%	235
One Global Service Provider LtdONEGLOBALONEGLOBAL	₹1,025 Cr	₹1,025 Cr	₹6 Cr	₹1 Cr	22.2%	₹1 Cr	17.3%	17.6%	19.5%	—
Health X Platform LimitedHEALTHXHEALTHX	₹868 Cr	₹890 Cr	₹1,468 Cr	₹-67 Cr	-4%	₹-20 Cr	-0.1%	—	0.2%	—
Gaudium Ivf And Women Health LimitedGAUDIUMIVFGAUDIUMIVF	₹797 Cr	₹820 Cr	₹104 Cr	₹38 Cr	36.1%	₹24 Cr	23.4%	23.1%	16.1%	92
Aspira Pathlab & Diagnostics LtdASPIRAASPIRA	₹135 Cr	₹136 Cr	₹22 Cr	₹4 Cr	16%	₹2 Cr	9.2%	17.5%	18.1%	16

Suraksha Diagnostic Limited

About

Key insights

Key risks

Growth drivers

Quick read

Pros

Cons

Research score

Revenue & net profit

Margins

Peers

Financials

Profit & loss

Balance sheet

Cash flow

Compounded returns

Compounded sales growth

Compounded profit growth

Return on equity

Ratios

Ratio timeline

Shareholding

Quarterly record

F&O

Not in the F&O segment

Fund holders

Documents

Announcements

Annual reports

Credit ratings

Investor Presentation and earnings call

Events

Dividends1

Announcements

Ratio timeline

Not in the F&O segment

Quarterly record

Insider dealing

Bulk & block deals

Board and management

Dividends1

Announcements

Annual reports

Credit ratings

Investor Presentation and earnings call

Profit & loss

Balance sheet

Cash flow

Compounded returns

Compounded sales growth

Compounded profit growth

Return on equity

1

1